<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561467</url>
  </required_header>
  <id_info>
    <org_study_id>17-134</org_study_id>
    <nct_id>NCT03561467</nct_id>
  </id_info>
  <brief_title>Oral Chemotherapy and Quality of Care</brief_title>
  <acronym>PARCOURS</acronym>
  <official_title>Community and Hospital Experiences for Patients Treated by Oral Chemotherapy at the University Hospital of Caen: Analysis of the Process and Its Dysfunctions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MSD France</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PARCOURS is a non-interventional research study evaluating dysfunctions in the continuous
      city-hospital journey of a patients cohort treated by oral chemotherapy (60 patients followed
      for 3 months).

      References used are the National Cancer Institute recommendations for the oral chemotherapy
      treated outpatients.

      Parameters found are : information exchanged, ambulatory and hospital monitoring in case of
      adverse event and adherence to treatment. The study includes also a medico-economic
      evaluation (hospitalization and transport spending in case of dysfunction in the patient's
      journey). Deviations will be analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Anticipated">September 29, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of dysfunctions</measure>
    <time_frame>3 months</time_frame>
    <description>Number of dysfunctions objectified during the 3-month follow-up period, by sub-processes of the course</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug adherence</measure>
    <time_frame>3 months</time_frame>
    <description>measured by Morisky-Green's questionnaire to the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug adherence</measure>
    <time_frame>3 months</time_frame>
    <description>measured by Data on the refill of prescriptions with the National Health Insurance, and evaluated according to the Drug Possession Ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expenses related to the use of unplanned hospital care</measure>
    <time_frame>3 months</time_frame>
    <description>Expenses related to the use of unplanned hospital care during the follow-up period: number of oncologist consultations, transport spending, emergency rehospitalizations and additional examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of the patient</measure>
    <time_frame>At month 3</time_frame>
    <description>RESOCAN questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of the caregiver</measure>
    <time_frame>At month 3</time_frame>
    <description>RESOCAN questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of the local professionals</measure>
    <time_frame>At month 3</time_frame>
    <description>RESOCAN questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patients</measure>
    <time_frame>At month 3</time_frame>
    <description>QLQC 30</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Evaluation of dysfunctions in the continuous city-hospital journey of a patients cohort treated by oral chemotherapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult outpatients treated by oral chemotherapy for a cancer disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years old

          -  Suffering from cancer (hematological malignancies, digestive tumors, thoracic tumors
             or cutaneous tumors)

          -  With an oral anticancer chemotherapy initial prescription written by an oncologist or
             hematologist from the University Hospital of Caen, whatever the place of the drug
             dispensing (Community pharmacy or hospital pharmacy )

        Exclusion Criteria:

        - Patient treated by oral anticancer chemotherapy for another pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valérie CHEDRU-LEGROS, PhD</last_name>
    <phone>+332 31 06 46 66</phone>
    <email>chedru-v@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Caen University Hopsital</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Chedru-Legros, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>June 7, 2018</last_update_submitted>
  <last_update_submitted_qc>June 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

